Results from the OPTIMIZE trial reported

The OPTIMIZE randomized trial comparing a novel, low-profile drug-eluting stent (DES) facilitating transradial access (TR) and direct stenting (DS) to existing DES did not establish non-inferiority of the new stent based on the prespecified study